The SOTAX Group, a global leader in the development and manufacturing of dissolution testing, automated sample preparation and physical testing equipment for the pharmaceutical industry, has acquired Dr. Schleuniger® Pharmatron.
Dr. Schleuniger® Pharmatron, with headquarters in Thun, Switzerland and a US subsidiary in Manchester, NH, is a company engaged in the engineering and manufacturing of equipment for the physical testing of pharmaceutical dosage forms, such as tablets, capsules, ampules, and other solid dosage forms.
With this acquisition, the SOTAX Group strengthens its global leadership position as a solution provider for the pharmaceutical industry and becomes the world’s largest manufacturer of equipment for testing the physical properties of pharmaceutical dosage forms.
“The acquisition and integration of Dr. Schleuniger® Pharmatron is a further step towards ensuring sustainable growth by strengthening our innovation leadership. The Dr. Schleuniger® Pharmatron brand stands for a long history of high quality and innovative technology. This will complement our existing product lines in an ideal way,” explains Thomas Pfammatter, CEO of the SOTAX Group.
“Being part of a leading global company with the worldwide sales and service capabilities of the SOTAX Group will open up new opportunities for us. It puts us in a position to serve our customers and partners even better,” says Martin Strehl, Chairman of the Board & CEO of Dr. Schleuniger® Pharmatron.
Dr. Schleuniger® Pharmatron’s Manchester, NH based operations will be integrated into the Westborough, MA based Americas organization of SOTAX Group. The Thun, Switzerland site of Dr. Schleuniger® Pharmatron will remain as a separate entity and become the hub of the physical testing business of the SOTAX Group.
Leveraged by the extensive worldwide sales and service network of SOTAX, product and application specialists from Dr. Schleuniger® Pharmatron and SOTAX will continue to deliver best-in-class service and support to our customers.